Group 1 - Double-Helix Pharmaceutical announced that its associate, Changfeng Pharmaceutical, is expected to be listed on the Hong Kong Stock Exchange on October 8, 2025, with a global offering of 41.198 million shares priced at HKD 14.75 each. Double-Helix holds approximately 3.68% of Changfeng's shares, with a lock-up period of 12 months post-listing [1] - Changfeng Pharmaceutical is involved in the pharmaceutical industry, specifically in the research and development of gene-engineered drugs [2] Group 2 - Lio Corporation has submitted an application to the Hong Kong Stock Exchange for issuing H-shares and listing on the main board [3] - Lio Corporation operates in the mechanical manufacturing and digital marketing sectors [3] Group 3 - Changjiang Securities received approval from the China Securities Regulatory Commission to issue corporate bonds totaling no more than CNY 20 billion, valid for 24 months [4] - Changjiang Securities provides services such as securities and futures brokerage, financial product distribution, investment advisory, asset custody, and margin financing [4] Group 4 - Jingye Intelligent plans to acquire 51% of Hefei Shengwen Information Technology for CNY 108 million, focusing on engineering information technology and intelligent products [5][6] - Jingye Intelligent specializes in the research, development, production, and sales of special robots and intelligent equipment systems [6] Group 5 - Aimeike's subsidiary received approval for the registration of Minoxidil topical solution, a non-prescription drug for treating hair loss [7][8] - Aimeike is engaged in the research, development, production, and sales of biomedical materials and biopharmaceuticals [8] Group 6 - Dalian Heavy Industry expects a net profit of CNY 474 million to CNY 508 million for the first three quarters of 2025, representing a year-on-year increase of 19.91% to 28.52% [9] - Dalian Heavy Industry specializes in the design, manufacturing, assembly, and installation of major technical equipment [9] Group 7 - Huayou Cobalt signed supply agreements with LGES for a total of approximately 76,000 tons of ternary precursor products from 2026 to 2030 [10][11] - Huayou Cobalt focuses on the research, manufacturing, and sales of new energy lithium battery materials and cobalt new materials [11] Group 8 - Zhenjiang Co. plans to reduce its shareholding by up to 5.529 million shares, not exceeding 3% of the total share capital, due to personal funding needs [12] - Zhenjiang Co. is involved in the design, processing, and sales of wind power equipment and components [12] Group 9 - Watson Bio's subsidiary received a drug registration certificate for a 13-valent pneumococcal polysaccharide conjugate vaccine for children [14][15] - Watson Bio specializes in the research, development, production, and sales of human vaccines and biopharmaceuticals [15] Group 10 - Yikang Pharmaceutical's major shareholder plans to reduce holdings by up to 42 million shares, not exceeding 2.04% of the total share capital, due to personal funding needs [16] - Yikang Pharmaceutical is engaged in the production and sales of excipients, raw materials, finished drugs, and new energy materials [16] Group 11 - Sichuan Gold's shareholder plans to reduce holdings by up to 7.56 million shares, accounting for 1.80% of the total share capital [19] - Sichuan Gold focuses on the construction, mining, and sales of gold mines [19] Group 12 - Kangchen Pharmaceutical received approval for a clinical trial of an innovative drug for treating advanced esophageal squamous cell carcinoma [20][21] - Kangchen Pharmaceutical specializes in the manufacturing of chemical drug formulations [21] Group 13 - UCloud plans to repurchase shares worth between CNY 8 million and CNY 10 million for employee stock ownership plans [22] - UCloud provides cloud computing services centered on IT infrastructure [22] Group 14 - Woton Technology announced an adjustment to its share repurchase plan, raising the price cap to CNY 60 per share [24] - Woton Technology specializes in the research, manufacturing, and sales of separation membrane products [24] Group 15 - Five Continents Medical announced plans for shareholders to reduce holdings by up to 126,530 shares, accounting for 1.8606% of the total share capital [26] - Five Continents Medical focuses on the research, manufacturing, and sales of disposable sterile infusion medical devices [26] Group 16 - CIMC Group plans to repurchase A-shares with a total amount not exceeding CNY 5 billion [27] - CIMC Group specializes in logistics and energy equipment solutions [27] Group 17 - Zhifei Biological's subsidiary received a drug registration certificate for a trivalent influenza vaccine suitable for individuals aged 3 and above [29][30] - Zhifei Biological is involved in the research, development, production, and sales of vaccines and biological products [30]

Group 1 - Double-Crane Pharmaceutical's associate company, Changfeng Pharmaceutical, is expected to officially list on the Hong Kong Stock Exchange on October 8, 2025, with stock code 02652.HK [1] - After the completion of the offering, Double-Crane Pharmaceutical will hold a total of 15.1657 million shares in Changfeng Pharmaceutical, which is expected to account for 3.68% of the total shares after issuance [1] Group 2 - LEO Holdings has submitted an application to the Hong Kong Stock Exchange on September 29, 2025, for the issuance of overseas listed shares (H shares) and for listing on the main board of the Hong Kong Stock Exchange [1]

Core Viewpoint - The company, LEO Group (002131.SZ), has submitted an application for the issuance of overseas listed shares (H-shares) and for listing on the main board of the Hong Kong Stock Exchange on September 29, 2025 [1] Group 1 - The application was submitted to the Hong Kong Stock Exchange and is in compliance with the requirements set by the Hong Kong Securities and Futures Commission [1] - The application materials were published on the Hong Kong Stock Exchange's website on the same day [1] - The submitted materials are in draft form and may be updated and revised as necessary [1]

Core Viewpoint - The company, Liao Group (002131), has submitted an application for the issuance of overseas listed shares (H shares) and for listing on the main board of the Hong Kong Stock Exchange on September 29, 2025 [1] Group 1 - The application materials for the issuance and listing were published on the Hong Kong Stock Exchange's website on the same day [1]

智通财经APP讯，利欧股份(002131.SZ)公告，公司已于2025年9月29日向中国香港联交所递交了发行境 外上市股份(H股)并在联交所主板挂牌上市的申请，并于同日在联交所网站刊登了本次发行上市的申请 材料。 ...

证券代码：002131 证券简称：利欧股份 公告编号：2025-058 利欧集团股份有限公司 关于向香港联交所递交境外上市股份（H 股）发行上市申请 并刊发申请资料的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 利欧集团股份有限公司 利欧集团股份有限公司（以下简称"公司"）已于2025年9月29日向香港联合交 易所有限公司（以下简称"香港联交所"）递交了发行境外上市股份（H股）并在香 港联交所主板挂牌上市（以下简称"本次发行上市"）的申请，并于同日在香港联 交所网站刊登了本次发行上市的申请材料。该申请材料为公司按照香港证券及期货 事务监察委员会（以下简称"香港证监会"）及香港联交所的要求编制和刊发，为 草拟版本，其所载资料可能会适时作出更新及修订。 公司本次发行上市尚需取得中国证券监督管理委员会、香港证监会、香港联交 所等相关政府部门、监管机构、证券交易所的批准或备案，并需综合考虑市场情况 以及其他因素方可实施，该事项仍存在不确定性。公司将根据相关事项的进展情况， 严格按照相关法律法规的规定与要求，及时履行信息披露义务，敬请广大投资者注 意投资风险。 ...

Core Viewpoint - Lio Co., Ltd. has submitted a listing application to the Hong Kong Stock Exchange, with Huatai International and China Galaxy International as sponsors [1] Group 1: Business Overview - Lio Co., Ltd. operates with a dual core business model of AI-driven digital marketing and smart pumps and systems, creating unique industrial barriers through complementary advantages [1] - In the smart pumps and systems sector, the company ranks second in China and thirteenth globally, establishing itself as the leading provider in the domestic civil pump export market [1] - The company's products are distributed across over 160 countries and regions [1]

Core Viewpoint - Liou Co., Ltd. is officially applying for a dual listing on the Hong Kong Stock Exchange, aiming for A+H listing, supported by leading underwriters Huatai International and China Galaxy International, with core business driven by AI across two major sectors [1] Financial Performance - The company is projected to achieve steady revenue growth from 2022 to 2024, reaching 21.171 billion yuan, indicating strong financial health and risk resilience [1] - The cash flow is stable, with a collection rate exceeding 90% in the pump business and an accounts receivable turnover period of only 93 days in digital marketing [1] Business Segments - In the AI digital marketing sector, the company is expected to rank first in revenue in the Chinese market by 2024, holding an 8.72% share of the advertising agency market, also the highest in the industry [1] - In the smart pump and systems segment, the company ranks second in domestic revenue and thirteenth globally, with the highest export value of civilian pumps in the country [1]

Core Viewpoint - Liou Co., Ltd. has submitted an application to the Hong Kong Stock Exchange, focusing on "AI-driven digital marketing and smart pumps and systems" as its core business model, which creates a unique industrial barrier and supports stable development [1] Group 1: Business Overview - Liou Co., Ltd. operates with a dual-core business model of "AI digital marketing + smart pumps and systems," which allows for complementary advantages and collaborative empowerment [1] - The AI digital marketing segment is projected to achieve the largest revenue scale in China's digital marketing market by 2024, holding a market share of 8.72% in the digital advertising agency sector, ranking first in the industry [1] - The smart pumps and systems segment ranks second in China's pump and system industry and thirteenth globally by revenue in 2024, with the highest export value in the domestic civil pump sector [1] Group 2: Financial Performance - Total revenue for 2022, 2023, and 2024 is projected to be 20.268 billion, 20.471 billion, and 21.171 billion respectively, indicating stable growth [2] - The gross profit margin is expected to remain in the range of 8.4% to 8.9%, reflecting stable profitability [2] - As of June 30, 2025, the current ratio is projected to be 2.3, and the debt-to-asset ratio is 14.2%, indicating a healthy financial structure and strong risk resistance [2] Group 3: Cash Flow Management - The cash flow contribution from the two core businesses is stable, with the pump and system business achieving a cash flow recovery rate exceeding 90% due to a "payment before delivery" settlement model [2] - The digital marketing business effectively controls accounts receivable turnover days, projected to be 93 days in 2024, showcasing outstanding overall working capital management [2]

Core Insights - Lio Co., Ltd. has submitted an application to the Hong Kong Stock Exchange, focusing on "AI-driven digital marketing and smart pumps and systems" as its core business model [1] - The company operates with a dual-core business model that combines AI digital marketing and smart pumps, creating unique industry barriers and providing robust support for stable development [1] Business Performance - Lio's AI digital marketing business is projected to achieve the largest revenue in China's digital marketing market by 2024, holding a market share of 8.72% in the digital advertising agency sector, ranking first in the industry [1] - The smart pumps and systems segment ranks second in China's pump and system industry and thirteenth globally by revenue in 2024, with the highest export value in the domestic civil pump sector [1] Financial Health - Total revenues for 2022, 2023, and 2024 are projected to be 20.268 billion, 20.471 billion, and 21.171 billion yuan respectively, indicating stable growth [2] - The gross profit margin is expected to remain between 8.4% and 8.9%, reflecting stable profitability [2] - As of June 30, 2025, the current ratio is projected to be 2.3, and the debt-to-asset ratio is 14.2%, indicating a healthy financial structure and strong risk resistance [2] Cash Flow Management - The cash flow from the two core businesses is stable, with the pump and system business achieving a cash collection rate exceeding 90% due to a "payment before delivery" settlement model [2] - The digital marketing business optimizes settlement with leading media platforms, effectively controlling accounts receivable turnover days, projected to be 93 days in 2024 [2]